Shott Joseph P, McGrath Shannon M, Pau Maria Grazia, Custers Jerome H V, Ophorst Olga, Demoitié Marie-Ange, Dubois Marie-Claude, Komisar Jack, Cobb Michelle, Kester Kent E, Dubois Patrice, Cohen Joe, Goudsmit Jaap, Heppner D Gray, Stewart V Ann
Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Vaccine. 2008 Jun 2;26(23):2818-23. doi: 10.1016/j.vaccine.2008.03.080. Epub 2008 Apr 16.
Falciparum malaria vaccine candidates have been developed using recombinant, replication-deficient serotype 5 and 35 adenoviruses (Ad5, Ad35) encoding the Plasmodium falciparum circumsporozoite surface protein (CSP) (Ad5.CS, Ad35.CS) (Crucell Holland BV, Leiden, The Netherlands). To evaluate the immunogenicity of these constructs, BALB/cJ mice were immunized twice with either Ad5.CS, Ad35.CS, empty Ad5-vector (eAd5), empty Ad35 vector (eAd35), or saline. Another group received the CSP-based RTS,S malaria vaccine formulated in the proprietary Adjuvant System AS01B (GlaxoSmithKline Biologicals, Rixensart, Belgium). Here we report that Ad5.CS, Ad35.CS, and RTS,S/AS01B, elicited both cellular and serologic CSP antigen-specific responses in mice. These adenoviral vectors induce strong malaria-specific immunity and warrant further evaluation.
已使用编码恶性疟原虫环子孢子表面蛋白（CSP）的重组、复制缺陷型5型和35型腺病毒（Ad5、Ad35）开发了恶性疟原虫疟疾候选疫苗（Ad5.CS、Ad35.CS）（荷兰莱顿Crucell Holland BV公司）。为评估这些构建体的免疫原性，用Ad5.CS、Ad35.CS、空Ad5载体（eAd5）、空Ad35载体（eAd35）或生理盐水对BALB/cJ小鼠进行两次免疫。另一组接受了以专有佐剂系统AS01B（比利时里克森萨特葛兰素史克生物制品公司）配制的基于CSP的RTS,S疟疾疫苗。在此我们报告，Ad5.CS、Ad35.CS和RTS,S/AS01B在小鼠中引发了细胞和血清学CSP抗原特异性反应。这些腺病毒载体诱导了强大的疟疾特异性免疫，值得进一步评估。
